New drug combo aims to tackle tough brain tumors in NF1 patients

NCT ID NCT07521657

Not yet recruiting Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug mirdametinib, alone or with radiation, in people with NF1-related high-grade gliomas (aggressive brain tumors). It includes three groups: those with recurrent sporadic glioblastoma, newly diagnosed NF1-associated glioblastoma, and other NF1-related high-grade gliomas. The goal is to see if the treatment improves survival or shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mirdametinib
What this could lead to: If successful, this could point toward a new treatment option for people with NF1-related high-grade gliomas, potentially improving survival and tumor control.
What could go wrong: This is an early-phase trial with only 55 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE GRADE 4 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma IDH-wildtype glioblastoma malignant glioma neurofibromatosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS 1 (NF1)

Contacts and locations

Locations

Childrens of Alabama

Birmingham, Alabama, 34294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.